Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Abstract Translational research plays a key role in drug development and biomarker discovery for hepatocellular carcinoma (HCC). However, unique challenges exist in this field because of the limited availability of human tumor samples from surgery, the lack of homogenous oncogenic driver mutations,...
Main Authors: | Valerie Chew, Chien-Huai Chuang, Chiun Hsu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Journal of Biomedical Science |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12929-024-01011-y |
Similar Items
-
Discovery of Small Molecules That Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies
by: Shailima Rampogu, et al.
Published: (2019-03-01) -
bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
by: Gehan Xu, et al.
Published: (2022-10-01) -
Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report
by: Xin Jiang, et al.
Published: (2024-05-01) -
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
by: Mimma Rizzo, et al.
Published: (2022-08-01) -
Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
by: Liting Zhong, et al.
Published: (2021-05-01)